- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05009095
The Listening Program® With Bone Conduction Headphones Changes Hypersensitivity to Sound and Behavioral Responses
The Listening Program With Bone Conduction Headphones Changes Hypersensitivity to Sound and Behavioral Responses Associated With Flight/Fight Responses of Children With Autism Spectrum Disorder Therefore Increasing Adaptive Life Skills
There are limited approaches to specifically address auditory sensory over- and under-responsivity (SOR) in children with Autism Spectrum Disorder (ASD). Exposure therapy (or systematic desensitization) may be a treatment option; researchers are investigating this approach. Many children receive sensory integration therapy, but this approach does not specifically target auditory SOR. Some families are advised to have their children avoid noxious stimuli or use compensatory techniques such as wearing headphones or ear plugs. While preliminary research suggests that use of noise attenuating headphones may reduce sympathetic activation for children with ASD and auditory SOR, this approach does not seek to change or alter the underlying cause of sympathetic activation (Pfeiffer et al., 2019).
Sound-based interventions are promising options to treat hyperacusis and subsequent auditory SOR in children with ASD. The objective of this study is to investigate changes in adaptive life skills and behavioral responses in children with ASD using Advanced Brain Technology's The Listening Program ® Spectrum music utilizing Waves ™ (bone conduction) headphones.
Our study will investigate the effects of a sound-based intervention developed in 2012 to specifically address the needs of children with ASD and children with hyperacusis and/or auditory SOR - The Listening Program® Spectrum music utilizing Waves™ (bone conduction) headphones by Advanced Brain Technologies. This program emphasizes low frequency music over an extended period of time; the duration recommended by Advanced Brain Technologies is 40 weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Richardson, Texas, United States, 75082
- Childrens's Health Specialty Center Richardson
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Children will be eligible to participate in this study if they are:
- Between the ages of 5 and 10 years old
- Diagnosis of autism spectrum disorder
- Auditory SOR defined by "Some Problems or Definite Dysfunction" on the Hearing section on the Sensory Processing Measure Home Form.
- Caregiver must be available to supervise listening sessions at home
- English Speaking
Exclusion Criteria:
1. Children will be excluded from the study if they are:
a. Diagnosed with seizure disorder b. Hearing impairments c. Cerebral palsy d. Fragile X syndrome or genetic disease e. Previous use of a listening base system f. Non-English speakers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: The Listening Program® with bone conduction headphones
The Listening Program ® Spectrum music requires a person listen to psycho-acoustically modified classical music online using specialized "Waves" ™ headphones. The headphones transmit sound through bone conduction which provides another mode of perceiving sound (https://advancedbrain.com). The Listening Program ® can be carried out in the home environment with either the base schedule, two fifteen minute sessions at least 30 minutes apart, or a condensed schedule for 30 minutes. Bone conduction allows the listening experience to go deeper into the vestibular system which is purported to reduce stress, help regulate the "fight or flight" response, and allow the listener to achieve a state of calm and relaxed alertness. This theory is based on the function of the vagus nerve, the 10th cranial nerve, which has branches that extend to the eardrum. Stimulation of the vagus nerve stimulates the parasympathetic nervous system (Allen, 2008). |
The Listening Program method of Music-Based Auditory Stimulation is enhanced with the addition of bone conduction technology with the ABT Bone Conduction System.
Bone Conduction combines the experience of listening to music through modified headphones adding subtle, synchronized acoustic vibration of the skin and skeletal system, engaging the whole body and brain in the listening process.
This multi-sensory approach accelerates and expands the benefits of The Listening Program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Adaptive Behavior Assessment System, Third Edition Score (ABAS-3) Score
Time Frame: To be administered at baseline, 1-week following a 40-week use of the listening program, and 3-months following treatment.
|
The ABAS-3 measures adaptive skills and provides a General Adaptive Composite, which is the overall score summarizing an individual's adaptive functioning.
The ABAS-3 is a norm-referenced test and the General Adaptive Composite is a standard score with a mean of 100 and a standard deviation of 15, with practical score ranges typically from ~40 to ~160.
Higher scores represent improvement, or higher levels of function; lower scores represent lower levels of function.
Scores between 90 - 109 are considered to be average, scores between 80 - 89 are below average, scores between 71 - 79 are low, and scores of 70 or less are extremely low.
|
To be administered at baseline, 1-week following a 40-week use of the listening program, and 3-months following treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pediatric Evaluation of Disability Inventory Computer Adaptive Test With ASD Scales (PEDI-CAT (ASD))
Time Frame: To be administered at baseline, 1-week following a 40-week use of the listening program, and 3-months following treatment
|
The PEDI-CAT measures functional abilities, and the ASD module has been adapted for use with children and youth with ASD.
This study used the Daily Activities and Social/Cognitive domains of the PEDI-CAT (ASD).
The PEDI-CAT (ASD) provides a scaled score (converted from raw responses using domain-specific (IRT) item-response parameters) for each domain - this score is not norm-referenced, so does not compare children to same-aged peers.
For each domain, the minimum scaled score is 20 and the maximum is 80.
Higher scores represent improvement, or higher levels of function; lower scores represent lower levels of function.
|
To be administered at baseline, 1-week following a 40-week use of the listening program, and 3-months following treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensory Processing Measure™ (SPM™)
Time Frame: To be administered at baseline, 1-week following a 40-week use of the listening program, and 3-months following treatment
|
The Sensory Processing Measure (SPM) measures sensory integration/sensory processing.
This study used the Home Form, which gathered information about participants' behavior, coordination, and participation at home.
The SPM provides a Total Sensory System score, which is an overall score summarizing an individual's sensory processing.
The SPM is a norm-referenced test and the Total Sensory System score is a T-score with a mean of 50 and a standard deviation of 10 (scale range- 20 to 80).
Lower scores represent improvement, or less sensory dysfunction; higher scores represent higher levels of sensory dysfunction.
Scores between 40 - 59 represent typical performance, scores between 60 - 69 represent some problems, and scores between 70 - 80 represent a definite dysfunction with sensory processing.
|
To be administered at baseline, 1-week following a 40-week use of the listening program, and 3-months following treatment
|
|
Autism Treatment Evaluation Checklist (ATEC)
Time Frame: To be administered at baseline, 1-week following a 40-week use of the listening program, and 3-months following treatment
|
The ATEC is a 77-item assessment tool developed at the Autism Research Institute.
It was developed to provide a free, easily accessible, and valid tool to measure changes in ASD symptoms over time.
The ATEC consists of four subtest scales: Speech/Language/Communication, Sociability, Sensory/Cognitive Awareness, and Health/Physical Behavior.
The four subscale scores are used to calculate a total score (77 items - score range 0 to 180).
A lower score indicates less severe symptoms of ASD and a higher score correlates with more severe symptoms of ASD.
Baseline scores can be compared with post-intervention scores to assist with determining intervention efficacy.
|
To be administered at baseline, 1-week following a 40-week use of the listening program, and 3-months following treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Suzanne Vercontaire, Children's Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU-2019-1698
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Istituto Clinico HumanitasRecruitingAutism | Autism Spectrum Disorder (ASD) | Autism DisorderItaly
-
The Children's Hospital of Zhejiang University...Not yet recruitingAutism | Autism Spectrum Disorder (ASD)China
-
Poznan University of Physical EducationCompletedAutism | Autism Spectrum Disorder (ASD)Poland
-
Greater Atlanta Integrative PediatricsRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Adia Med of Winter Park LLCActive, not recruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Poznan University of Physical EducationNational Science Centre, PolandCompletedAutism Spectrum Disorder | ASD | Autism Spectrum Disorder High-Functioning | Autism SpectrumPoland
-
Stanford UniversityJohn and Marcia Goldman FoundationNot yet recruitingAutism | Autism Spectrum Disorder (ASD)United States
-
Blinklab LimitedRecruitingAutism Spectrum Disorder | Autism | Neurodevelopmental Conditions | Autism Spectrum Disorder (ASD)United States
-
National Cheng-Kung University HospitalCompletedAutism Spectrum Disorder (ASD) | Autism Spectrum Disorder High-FunctioningTaiwan
-
University of California, Los AngelesUniversity of WashingtonRecruitingAutism Spectrum Disorder (ASD)United States
Clinical Trials on The Listening Program® with bone conduction headphones
-
Nantes University HospitalRecruiting
-
Paolo PesceCompletedEdentulous Alveolar RidgeItaly
-
Medical University InnsbruckCompletedAcute Kidney Injury | Critically Ill | Renal Replacement Therapy | Continuous Renal Replacement Therapy | Continuous Veno-Venous Hemofiltration | Replacement Fluid | Phoxilium | Biphozyl | Anticoagulation | Regional Citrate AnticoagulationAustria
-
Universidad Europea de MadridCompleted
-
Umm Al-Qura UniversityCompletedPHYSICAL THERAPY TECHNIQUESSaudi Arabia
-
Abbott Medical DevicesCompletedSystolic Heart FailureAustralia, Hong Kong, Japan
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKline; University of WashingtonCompletedProstate Cancer | Castration-resistant, MetastaticUnited States